What Treatment Should We Dare in Patients With In-Stent Restenosis?
JACC Cardiovasc Interv
.
2018 Feb 12;11(3):284-286.
doi: 10.1016/j.jcin.2017.11.024.
Authors
Adnan Kastrati
1
,
Michael Joner
2
,
Sebastian Kufner
3
Affiliations
1
Deutsches Herzzentrum München, Technische Universität München, Munich, Germany; DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany. Electronic address: kastrati@dhm.mhn.de.
2
Deutsches Herzzentrum München, Technische Universität München, Munich, Germany; DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany.
3
Deutsches Herzzentrum München, Technische Universität München, Munich, Germany.
PMID:
29413243
DOI:
10.1016/j.jcin.2017.11.024
No abstract available
Keywords:
bare-metal stent(s); drug-eluting balloon; drug-eluting stent(s); restenosis.
Publication types
Editorial
Comment
MeSH terms
Coronary Restenosis*
Drug-Eluting Stents
Everolimus*
Humans
Paclitaxel
Stents
Substances
Everolimus
Paclitaxel